Biatain®
Biatain® Alginate Ag
Biatain® Alginate Ag is a highly absorbent silver alginate dressing for moderately to heavily exuding infected wounds of many sizes, shapes and depths.
Biatain®
Biatain® Alginate Ag
Product description
Recommended for cavity filling for infected wounds
The design and structural integrity of the dressing allow you to cut the dressing to fit wounds of many sizes, shapes and depths.
Patented wound dressing containing a silver complex with broad antimicrobial profile
Biatain® Alginate Ag provides continuous antibacterial effect during the entire wear time (up to 7 days) (2).
High dressing integrity
The high dressing integrity allows for one-piece removal with minimal pain and trauma (1).
Minimized risk of leakage and maceration
The absorption of Biatain® Alginate Ag (1) and the gel formation which locks exudate inside the gel prevent leakage that can cause maceration of the periwound skin.
Documented hemostatic effect
Contrary to hydrofibre dressings, Biatain® Alginate Ag has documented hemostatic effect, i.e. the ability to arrest blood flow in minor bleedings (4,5).
Mode of action
On contact with wound exudate, Biatain® Alginate Ag converts to a soft, cohesive gel that conforms closely to the wound bed for optimal infection control. The silver complex releases ions in the presence of wound exudate.
Product composition
Biatain® Alginate Ag is an alginate dressing consisting of alginate, carboxymethylcellulose (CMC) and an ionic silver complex.
Usage
Biatain® Alginate Ag can be used on all moderate to heavily exuding partial to full thickness wounds. Biatain® Alginate Ag may be used on infected wounds or wounds at risk of infection. Biatain® Alginate Ag can be used under compression bandages. Biatain® Alginate Ag should not be used on dry or lightly exuding wounds or to control heavy bleeding. Biatain® Alginate Ag is indicated for leg ulcers, pressure ulcers, diabetic foot ulcers, donor sites, traumatic wounds, and second degree burns.
REFERENCES
1. Thomas S et al. www.dressings.org/TechnicalPublications/PDF/Coloplast-Dressings-Testing-2003-2004.pdf
2. Data on file (Independent laboratory testing performed by Wickham Laboratories).
3. http://www.worldwidewounds.com/1998/june/Alginates-FAQ/alginates-questions.html
4. Segal HC et al. The effects of alginate and non-alginate wound dressings on blood coagolation and platelet activation. Journal of Biomaterials Applications 1998:249-57.
5. Elalamy I and Robert F. Etude in vitro des effets proactivateurs plaquettaires de deux pansements: Alginate pur (Algostéril) et Alginate-CMC (SeaSorb Soft), etude sur plasma riche en plaquettes. CPC France 2007.
Unique 3D foam structure for superior absorption
When in contact with exudate, the unique 3D foam structure of Biatain® conforms to the wound bed for superior absorption – even under compression (2,6).
Soft and flexible dressing
Biatain® Ibu is a soft and flexible dressing that delivers high patient comfort. The bevelled edges reduce the risk of pressure marks (3).
Combines moist wound healing with local release of Ibuprofen
In the presence of exudate, there is a sustained release of a low dose of Ibuprofen into the wound bed throughout the wear time of the dressing (up to 7 days) (1,7).
Wound healing does not have to be painful
Comparative studies have shown a reduction in wound pain in patients wearing Biatain® Ibu compared with dressings without Ibuprofen (4,5).
Mode of action
Ibuprofen is released when the foam comes into contact with wound exudate (1,7).
Composition
Biatain® Ibu is an absorbent polyurethane foam that contains 0.5 mg/cm2 of Ibuprofen homogeneously dispersed throughout the foam matrix (1).
Usage
Biatain® Ibu Non-Adhesive is indicated for a wide range of low to highly exuding wounds. This includes acute wounds such as second degree burns, donor sites, postoperative wounds and skin abrasions: and chronic wounds such as leg ulcers, pressure ulcers and non-infected diabetic foot ulcers. Biatain® Ibu is suitable for use in combination with compression therapy.
REFERENCES
1. Jorgensen B et al. Pain and quality of life for patients with venous leg ulcers: Proof of concept of the efficacy of Biatain® - Ibu, a new pain reducing wound dressing. Wound repair and regeneration 2006:14(3): 233-39.
2. Thomas S et al. www.dressings.org/TechnicalPublications/PDF/Coloplast-Dressings-Testing-2003-2004.pdf
3. Kirby P. Quality of life, exudate management and the Biatain® foam dressing range. British Journal of Nursing 2008:17(15):S32-S37.
4. Gottrup F et al. Reducing wound pain in venous leg ulcers with Biatain® Ibu: A randomized, controlled double-blind clinical investigation on the performance and safety. Wound Repair and Regeneration 2008:6:615-25.
5. Palao i Domenech R et al. Effects of a foam dressing with ibuprofen on wound pain: results from an international, comparative real life study on painful, exuding wounds. Journal of Wound Care 2008:17(8):342-48.
6. Reitzel N et al. An in-vitro test of absorption capacity of foam dressings under pressure. EWMA 2008
7. Steffansen B and Herping S. Novel wound models for characterizing the effects of exudate levels on the controlled release of ibuprofen from foam dressings. EWMA 2006.
Product description
Recommended for cavity filling for infected wounds
The design and structural integrity of the dressing allow you to cut the dressing to fit wounds of many sizes, shapes and depths.
Patented wound dressing containing a silver complex with broad antimicrobial profile
Biatain® Alginate Ag provides continuous antibacterial effect during the entire wear time (up to 7 days) (2).
High dressing integrity
The high dressing integrity allows for one-piece removal with minimal pain and trauma (1).
Minimized risk of leakage and maceration
The absorption of Biatain® Alginate Ag (1) and the gel formation which locks exudate inside the gel prevent leakage that can cause maceration of the periwound skin.
Documented hemostatic effect
Contrary to hydrofibre dressings, Biatain® Alginate Ag has documented hemostatic effect, i.e. the ability to arrest blood flow in minor bleedings (4,5).
Mode of action
On contact with wound exudate, Biatain® Alginate Ag converts to a soft, cohesive gel that conforms closely to the wound bed for optimal infection control. The silver complex releases ions in the presence of wound exudate.
Product composition
Biatain® Alginate Ag is an alginate dressing consisting of alginate, carboxymethylcellulose (CMC) and an ionic silver complex.
Usage
Biatain® Alginate Ag can be used on all moderate to heavily exuding partial to full thickness wounds. Biatain® Alginate Ag may be used on infected wounds or wounds at risk of infection. Biatain® Alginate Ag can be used under compression bandages. Biatain® Alginate Ag should not be used on dry or lightly exuding wounds or to control heavy bleeding. Biatain® Alginate Ag is indicated for leg ulcers, pressure ulcers, diabetic foot ulcers, donor sites, traumatic wounds, and second degree burns.
REFERENCES
1. Thomas S et al. www.dressings.org/TechnicalPublications/PDF/Coloplast-Dressings-Testing-2003-2004.pdf
2. Data on file (Independent laboratory testing performed by Wickham Laboratories).
3. http://www.worldwidewounds.com/1998/june/Alginates-FAQ/alginates-questions.html
4. Segal HC et al. The effects of alginate and non-alginate wound dressings on blood coagolation and platelet activation. Journal of Biomaterials Applications 1998:249-57.
5. Elalamy I and Robert F. Etude in vitro des effets proactivateurs plaquettaires de deux pansements: Alginate pur (Algostéril) et Alginate-CMC (SeaSorb Soft), etude sur plasma riche en plaquettes. CPC France 2007.
Unique 3D foam structure for superior absorption
When in contact with exudate, the unique 3D foam structure of Biatain® conforms to the wound bed for superior absorption – even under compression (2,6).
Soft and flexible dressing
Biatain® Ibu is a soft and flexible dressing that delivers high patient comfort. The bevelled edges reduce the risk of pressure marks (3).
Combines moist wound healing with local release of Ibuprofen
In the presence of exudate, there is a sustained release of a low dose of Ibuprofen into the wound bed throughout the wear time of the dressing (up to 7 days) (1,7).
Wound healing does not have to be painful
Comparative studies have shown a reduction in wound pain in patients wearing Biatain® Ibu compared with dressings without Ibuprofen (4,5).
Mode of action
Ibuprofen is released when the foam comes into contact with wound exudate (1,7).
Composition
Biatain® Ibu is an absorbent polyurethane foam that contains 0.5 mg/cm2 of Ibuprofen homogeneously dispersed throughout the foam matrix (1).
Usage
Biatain® Ibu Non-Adhesive is indicated for a wide range of low to highly exuding wounds. This includes acute wounds such as second degree burns, donor sites, postoperative wounds and skin abrasions: and chronic wounds such as leg ulcers, pressure ulcers and non-infected diabetic foot ulcers. Biatain® Ibu is suitable for use in combination with compression therapy.
REFERENCES
1. Jorgensen B et al. Pain and quality of life for patients with venous leg ulcers: Proof of concept of the efficacy of Biatain® - Ibu, a new pain reducing wound dressing. Wound repair and regeneration 2006:14(3): 233-39.
2. Thomas S et al. www.dressings.org/TechnicalPublications/PDF/Coloplast-Dressings-Testing-2003-2004.pdf
3. Kirby P. Quality of life, exudate management and the Biatain® foam dressing range. British Journal of Nursing 2008:17(15):S32-S37.
4. Gottrup F et al. Reducing wound pain in venous leg ulcers with Biatain® Ibu: A randomized, controlled double-blind clinical investigation on the performance and safety. Wound Repair and Regeneration 2008:6:615-25.
5. Palao i Domenech R et al. Effects of a foam dressing with ibuprofen on wound pain: results from an international, comparative real life study on painful, exuding wounds. Journal of Wound Care 2008:17(8):342-48.
6. Reitzel N et al. An in-vitro test of absorption capacity of foam dressings under pressure. EWMA 2008
7. Steffansen B and Herping S. Novel wound models for characterizing the effects of exudate levels on the controlled release of ibuprofen from foam dressings. EWMA 2006.